Newsroom | 12543 results
Sorted by: Latest
-
Goodlabs Launches Free Clinical-Grade Bloodwork with Blood Donation at Inova CentreMed Site
CENTREVILLE, Va.--(BUSINESS WIRE)--Goodlabs partners with Inova to offer free wellness panels to blood donors, strengthening the blood supply and expanding access to health data....
-
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Inves...
-
SafeRide Health Ranks #14 on Inc.’s List of Fastest-Growing Companies in the Southwest
SAN ANTONIO--(BUSINESS WIRE)--SafeRide Health, a prominent provider of technology-enabled NEMT services, is ranked No. 14 on the Inc. 2026 Regionals: Southwest list....
-
Natus Sensory and Oaktree Products Announce Strategic Distribution Partnership to Expand Access to Diagnostic Audiology Solutions
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Natus Sensory, a global leader in sensory and diagnostic solutions, today announced a new strategic distribution partnership with Oaktree Products, a second-generation family-owned distributor of clinical supplies and diagnostic equipment to the hearing healthcare industry. The partnership is designed to expand market access to Natus Sensory’s diagnostic hearing assessment and fitting solutions across the United States by leveraging Oaktree’s deep relationship...
-
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of children and adults with SMA to the U.S...
-
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedside. Baxter’s launch of the product is the result of a strategic and exclusive distrib...
-
Retractable Technologies, Inc. Reports Results for 2025
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27, 2026 with the U.S. Securities and Exchange Commission. The Company’s revenues for 2025 increased 15.8%. The Company’s revenues were approximately $38.3 million in 2025 as compared to approximat...
-
Covalon Announces Grant of Deferred Share Units
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the Company has granted an aggregate of 97,674 Deferred Share Units (“DSUs”) to four of its non-employee directors that elected to receive all or a portion of their annual directors’ fees for fiscal year 2026 in DSUs as opposed to cash. The DSUs were granted under the Company's Amended and Restated Omnibus Long-Term...
-
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning January 1, 2026 through March 31, 2026. The dividends will be paid on April 20, 2026 to...
-
Irenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today issued the following statement regarding the Company’s recent announcement: “We welcome Teleflex's newfound openness to consider all strategic alternatives. As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder represent...